Literature DB >> 1319406

Binding of class II Escherichia coli enterotoxins to mouse Y1 and intestinal cells.

S T Donta1, T Tomicic, R K Holmes.   

Abstract

The binding of class II Escherichia coli heat-labile enterotoxins (LT) to Y1 tissue-cultured cells and mouse intestinal cells was studied and compared with that of class I toxins, including cholera enterotoxin. All radioiodinated (125I) toxins retained their biological activities in both model systems, but only LTIIb could be shown to bind specifically to target cells. LTIIa could inhibit the binding of both class I and LTIIb toxins, a finding which correlates with its ability to bind to multiple gangliosides. LTIIb could not inhibit the binding of the other enterotoxins. The binding and activity of class II toxins could not be modulated by prior exposure of target cells to the B subunit of LTI.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1319406      PMCID: PMC257247          DOI: 10.1128/iai.60.7.2870-2873.1992

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  22 in total

1.  Identification of regions on a 230-kilobase plasmid from enteroinvasive Escherichia coli that are required for entry into HEp-2 cells.

Authors:  P L Small; S Falkow
Journal:  Infect Immun       Date:  1988-01       Impact factor: 3.441

2.  Classification of enterotoxins on the basis of activity in cell culture.

Authors:  G T Keusch; S T Donta
Journal:  J Infect Dis       Date:  1975-01       Impact factor: 5.226

3.  Inhibition of the steroidogenic effects of cholera and heat-labile Escherichia coli enterotoxins by GM1 ganglioside: evidence for a similar receptor site for the two toxins.

Authors:  S T Donta; J P Viner
Journal:  Infect Immun       Date:  1975-05       Impact factor: 3.441

4.  Assay for enterotoxigenic Escherichia coli heat-stable toxin b in rats and mice.

Authors:  S C Whipp
Journal:  Infect Immun       Date:  1990-04       Impact factor: 3.441

5.  Net fluid secretion and impaired villous function induced by colonization of the small intestine by nontoxigenic colonizing Escherichia coli.

Authors:  T A Schlager; C A Wanke; R L Guerrant
Journal:  Infect Immun       Date:  1990-05       Impact factor: 3.441

6.  Infantile diarrhea produced by heat-stable enterotoxigenic Escherichia coli.

Authors:  R W Ryder; I K Wachsmuth; A E Buxton; D G Evans; H L DuPont; E Mason; F F Barrett
Journal:  N Engl J Med       Date:  1976-10-14       Impact factor: 91.245

7.  Molecular genetic analysis of ganglioside GD1b-binding activity of Escherichia coli type IIa heat-labile enterotoxin by use of random and site-directed mutagenesis.

Authors:  T D Connell; R K Holmes
Journal:  Infect Immun       Date:  1992-01       Impact factor: 3.441

8.  Variation in chemical properties and antigenic determinants among type II heat-labile enterotoxins of Escherichia coli.

Authors:  B E Guth; E M Twiddy; L R Trabulsi; R K Holmes
Journal:  Infect Immun       Date:  1986-11       Impact factor: 3.441

9.  Activation of Escherichia coli heat-labile enterotoxins by native and recombinant adenosine diphosphate-ribosylation factors, 20-kD guanine nucleotide-binding proteins.

Authors:  C M Lee; P P Chang; S C Tsai; R Adamik; S R Price; B C Kunz; J Moss; E M Twiddy; R K Holmes
Journal:  J Clin Invest       Date:  1991-05       Impact factor: 14.808

10.  Rabbit intestinal glycoprotein receptor for Escherichia coli heat-labile enterotoxin lacking affinity for cholera toxin.

Authors:  J Holmgren; P Fredman; M Lindblad; A M Svennerholm; L Svennerholm
Journal:  Infect Immun       Date:  1982-11       Impact factor: 3.441

View more
  2 in total

Review 1.  Enteric bacterial toxins: mechanisms of action and linkage to intestinal secretion.

Authors:  C L Sears; J B Kaper
Journal:  Microbiol Rev       Date:  1996-03

2.  Inhibition of heat-labile cholera and Escherichia coli enterotoxins by brefeldin A.

Authors:  S T Donta; S Beristain; T K Tomicic
Journal:  Infect Immun       Date:  1993-08       Impact factor: 3.441

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.